What Is MGF?

1. What is MGF, and where does the name come from?

The IGF-1 gene can be read in more than one way, a process called alternative splicing. Every version yields the same mature IGF-1 hormone, but each attaches a different tail, the E-domain, which is normally trimmed off. The main form is IGF-1Ea. The variant named MGF includes an extra stretch of genetic code from exon 5, which shifts the reading frame and produces a tail with a different makeup, according to Matheny and colleagues’ 2010 review.

Geoffrey Goldspink’s London group first cloned the variant in 1996 from rabbit muscle made to grow by active stretch. Yang and colleagues found it readily in stretched or exercised muscle but barely in resting muscle. The inserted segment is 49 base pairs long in humans and 52 in rodents, as noted by Kandalla’s team.

Why “MGF” can mean several different molecules

The single label covers molecules that behave differently. Research on one cannot be assumed to apply to another.

Janssen and colleagues’ 2016 receptor study shows why this matters. Full-length MGF contains the IGF-1 hormone and acts on the IGF-1 receptor, whereas the short peptide does not. The general peptide guide explains why the exact molecule matters more than a product name.

2. How is MGF supposed to work?

The original model proposed a two-step repair sequence. In rats, Hill and Goldspink reported that the MGF variant spikes soon after muscle damage and fades within days. That early pulse was thought to wake satellite cells, the stem cells that divide and fuse into damaged fibers. Splicing then shifts toward IGF-1Ea, which supplies mature IGF-1 to support protein synthesis.

Early cell work suggested the tail had its own action. In a mouse muscle cell line, Yang and Goldspink found the synthetic E-domain peptide boosted cell division and delayed maturation into fibers, even when the IGF-1 receptor was blocked.

Does the sold peptide exist in nature?

The 2010 Endocrinology review raised three objections. No 24-amino-acid peptide matching the synthetic product had been isolated from any tissue or fluid. No known enzyme cuts the precursor at the right spot to release it. And MGF mRNA in muscle had never been shown to approach IGF-1Ea levels, even early in repair (Matheny et al., 2010).

Later work partly answered the first point. Vassilakos and colleagues detected the longer Ec E-peptide in human and rodent muscle, liver and heart, and its levels shifted during regeneration after damaging exercise in people. That supports a natural E-peptide, not the specific short fragment sold online.

3. What happens to MGF when you exercise?

The firmest human data come from muscle biopsies that measure the body’s own MGF mRNA. These show the variant responds to loading and damage.

A blunted response with age also appeared in rats: Owino and colleagues linked older animals’ weaker reaction to overload with far lower MGF expression. This is why MGF is discussed in the context of age-related muscle loss.

The 2004 study involved recombinant growth hormone, a prescription drug, not MGF. None of these studies gave anyone synthetic MGF. They show that training changes the body’s own splicing; they cannot show that adding a peptide from a vial does the same job.

4. Did the cell and animal studies hold up?

Cell studies

The 2014 paper carries the most weight because it was designed as a replication, performed at two pharmaceutical companies including Novartis. Its authors wrote that their findings “call in to question” a physiological role for the peptide (Fornaro et al., 2014).

In the 2016 assays, full-length MGF eventually reached about the same peak IGF-1 receptor activation as IGF-1 but needed a higher concentration. Its EC50, the concentration producing half the maximal effect, was 7.83 nmol/L (95% CI 4.87–12.58) against 0.86 nmol/L (95% CI 0.69–1.07) for IGF-1. In practice, full-length MGF acts like a weaker IGF-1, not like the short peptide.

Animal studies

Several animal experiments, largely from groups that developed the MGF concept, reported protective effects. None has led to a human trial.

These used research-grade material or gene vectors, often placed directly in the target tissue under controlled conditions. They say nothing about whether a self-injected product grows muscle or speeds recovery in people.

5. Is MGF approved or legal?

No MGF product has been approved for therapeutic use, as Esposito and colleagues note, so there is no prescription version, labeled dose or approved route. A 2026 clinical review of GH- and IGF-1-axis peptides put PEG-MGF in its lowest evidence tier, meaning no peer-reviewed human studies, and judged claims of faster recovery or improved body composition unproven (Dominikowski et al., 2026).

In sport, MGF has been banned since 2005 (Thevis et al., 2014). The WADA 2026 Prohibited List names “mechano growth factors (MGFs)” in section S2.3, growth factors and growth factor modulators, prohibited both in and out of competition. The same section covers IGF-1 analogues such as IGF-1 LR3 and IGF-1 DES.

Tests exist. Full-length MGF was detectable at 0.25 ng/mL using adapted routine doping methods (Thevis et al., 2014), and one lab reported a mass-spectrometry marker that distinguishes the amidated analogue from the natural form (Esposito et al., 2012).

6. What dose of MGF has been studied, and what is its half-life?

There is no human dose to report. No controlled trial has given MGF to people, and there is no product label. The 500 ng/mL figure from the 2014 replication is a cell-culture concentration, not a dose for a person.

No study has measured absorption, half-life or clearance of any MGF peptide in humans, and half-life numbers circulating online could not be traced to a primary source. The closest data point is a test-tube experiment in which a seized MGF variant with one amino-acid substitution showed “good stability” in human plasma, and the authors expected it to be detectable in urine (Cox et al., 2017). That applies only to that variant and is not a human half-life. The half-life tracking guide explains why a half-life needs a defined product, route and population.

7. What are the side effects and risks of MGF?

No measured side-effect rates

Without human trials, there is no measured frequency of any adverse effect, no established safe amount and no interaction data. The 2026 review lists effects reported across unregulated GH- and IGF-1-axis peptides as a group, while stating that no human data exist for PEG-MGF itself:

• low or high blood sugar
• fluid retention
• muscle and joint pain
• injection-site reactions

Cancer questions

All the cancer-related findings are laboratory or tissue observations; none shows that MGF products cause cancer. Armakolas and colleagues found the variant far more strongly expressed in prostate cancer and precancerous tissue than in normal prostate, and the synthetic E peptide stimulated prostate cancer cell growth without needing the IGF-1 or insulin receptors.

In 83 prostate cancer surgical specimens, Savvani’s group linked higher IGF-1Ec to more advanced stage (p = 0.004) and, weakly, to higher Gleason score (r = 0.247). Separately, full-length MGF activates the IGF-1 receptor, the target of IGF-1 itself.

What seized vials contained

These products come from outside any regulated supply chain, so identity, amount, purity and sterility are uncontrolled.

8. Can MGF help with muscle loss on GLP-1 medicines?

No study has tested it. Losing weight by almost any route includes some lean mass, a topic covered in the GLP-1 and muscle loss guide. The MGF research does not address it: the human studies measured natural MGF after training, and no trial has given MGF to people taking semaglutide, tirzepatide or any other GLP-1 drug.

There are also no interaction data between MGF and these medicines. The only side-effect signals available are class-level reports from the 2026 review, which include changes in blood sugar, a point worth raising with a prescriber for anyone also taking glucose-lowering treatment.

The biopsy studies point in a different direction. The stimulus that reliably raised MGF expression in people was resistance or eccentric exercise, which a person can actually plan and record.

9. What can you actually measure or track?

No routine clinical test measures MGF exposure or confirms that it reached muscle. The biopsy measurements used in research are not practical outside a study, and anti-doping assays detect the presence of a product, not its effect.

Outcomes that can be measured are the ordinary ones: strength on repeatable lifts, body composition from a consistent method, body weight and, for anyone on a GLP-1 medicine, the dose schedule and side effects. Record training changes, protein intake, sleep and any new products alongside them. If several things change at once, a log cannot attribute a result to one of them. The peptide tracking guide covers how to keep those records usable when talking with a clinician.

10. MGF FAQ

• What does MGF do?

  In the body, the MGF splice variant is switched on in muscle after loading or damage and was proposed to activate muscle stem cells. Whether the synthetic peptide sold as MGF does this is disputed: early cell studies reported effects, but an independent industry replication found none.

• Is MGF legal?

  MGF has never been approved as a medicine, so there is no prescription product. WADA lists mechano growth factors under S2.3 and bans them in and out of competition, and has prohibited them since 2005.

• Does MGF build muscle in humans?

  This has not been tested. No randomized or controlled human trial of MGF has been published. The human data measure the body's own MGF mRNA after exercise, not the effect of injecting a synthetic peptide.

• What are the side effects of MGF?

  No human trial has measured them. A 2026 review lists low or high blood sugar, fluid retention, muscle and joint pain and injection-site reactions for unregulated GH and IGF-1-axis peptides as a class, while noting no human data exist for PEG-MGF specifically.

• How long does MGF stay in your system?

  Unknown. No study has measured the half-life or elimination of any MGF peptide in people. One test-tube study found a seized MGF variant was fairly stable in human plasma, which is not the same as a human half-life.

• What is the difference between MGF and PEG-MGF?

  PEG-MGF is the MGF peptide attached to polyethylene glycol and marketed as longer-acting. Neither form has published human trials, and a 2026 review placed PEG-MGF in its lowest evidence tier.

• Can MGF be used with semaglutide or tirzepatide?

  No study has combined MGF with any GLP-1 medicine, and there are no interaction data. MGF has not been shown to preserve muscle during weight loss, so it cannot be presented as a fix for lean-mass loss on these drugs.

• Can MGF be detected in a drug test?

  Yes. Anti-doping labs have published mass-spectrometry methods for MGF analogues, and full-length MGF was detectable at 0.25 ng/mL with adapted routine tests.

11. Sources